2143. A Qualitatitive Study of Barriers to Hepatitis C Treatment among People Living with HIV and Hepatitis C in the Era of Transition to Direct-Acting Agents
Session: Poster Abstract Session: HIV/HCV Coinfection and Liver Disease
Saturday, October 29, 2016
Room: Poster Hall
Background:

Rates of treatment uptake for hepatitis C virus (HCV) among people coinfected with human immunodeficiency virus (HIV) have historically been low, the result of numerous barriers to treatment. Although better-tolerated all-oral direct-acting agents (DAAs) are expected to improve rates of treatment uptake, some of the barriers to treatment might persist and continue to suppress rates of treatment uptake in the future. We performed a qualitiative study to help elucidate which barriers to HCV treatment might persist in the DAA era.

Methods:

In-depth, semistructured interviews were performed on a cohort of HIV/HCV coinfected patients who had not completed HCV treatment (n=16) as well as their primary care providers (n=8) with a focus on challenges relevant to the transition to DAA-based regimens. Interview transcripts were analyzed using an inductive thematic analysis approach. Data were first coded in ATLAS.ti using an open coding process. Once several emerging themes were repeated across more than one participant, descriptive codes and subcodes for each theme were defined. Memos were developed and diagramming was performed to evaluate relationships between themes.

Results:

We found two distinct subsets of patients, primarily distinguished by their level of knowledge of HCV. One group of patients was well-informed about HCV and HCV therapy. The major barrier for this group had been the side effect profile of interferon. In the second group, the primary barrier to treatment was a low level of knowledge of HCV. Multiple factors reinforced this lack of knowledge, including a lack of awareness of HCV in the community, a lack of education about HCV after diagnosis, socioeconomic disadvantage, and competing psychiatric and medical concerns, namely HIV. Providers expressed optimism in the DAAs, although this was tempered by concerns about the ongoing relevance of many of the socioeconomic and psychiatric barriers to care and concerns over the high cost of the DAAs.

Conclusion:

There is a large population of HIV/HCV coinfected patients who will continue to face significant barriers to HCV treatment. Intensive efforts to educate HIV/HCV coinfected patients about HCV and support them through treatment will be critical to ensure widespread success of the DAAs.

Matthew Scherer, MD1, Hong Van Tieu, MD1, Michael Yin, MD1 and Helen-Maria Lekas, PhD.2, (1)Medicine/Infectious Diseases, Columbia Presbyterian Medical Center, New York, NY, (2)Mailman School of Public Health, Center for the Psychosocial Study of Health & Illness, Columbia University, New York, NY

Disclosures:

M. Scherer, None

H. Van Tieu, None

M. Yin, None

H. M. Lekas, None

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.